BR112015010283A2 - bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, método de produzir uma glicoproteína recombinante, e, célula de e. coli modificada - Google Patents

bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, método de produzir uma glicoproteína recombinante, e, célula de e. coli modificada

Info

Publication number
BR112015010283A2
BR112015010283A2 BR112015010283A BR112015010283A BR112015010283A2 BR 112015010283 A2 BR112015010283 A2 BR 112015010283A2 BR 112015010283 A BR112015010283 A BR 112015010283A BR 112015010283 A BR112015010283 A BR 112015010283A BR 112015010283 A2 BR112015010283 A2 BR 112015010283A2
Authority
BR
Brazil
Prior art keywords
recombinant glycoprotein
modified
polysaccharide
producing
production
Prior art date
Application number
BR112015010283A
Other languages
English (en)
Other versions
BR112015010283A8 (pt
Inventor
Faridmoayer Amirreza
Kowarik Michael
Wacker Michael
Wetter Michael
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of BR112015010283A2 publication Critical patent/BR112015010283A2/pt
Publication of BR112015010283A8 publication Critical patent/BR112015010283A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

1 / 1 resumo “bactã‰ria gram-negativa modificada para a produã‡ãƒo de um polissacarãdeo, glicoproteãna recombinante, mã‰todo de produzir uma glicoproteãna recombinante, e, cã‰lula de e. coli modificada” sã£o aqui fornecidas cã©lulas procariã³ticas proficientes para produzir glicoconjugados in vivo, e tambã©m sã£o fornecidos mã©todos para gerar estas cã©lulas e mã©todos de usar estas cã©lulas para produzir glicoconjugados. as composiã§ãµes dos glicoconjugados mencionados tambã©m estã£o incluã­das e outrossim seus diferentes usos estã£o incluã­dos.
BR112015010283A 2012-11-07 2013-11-07 bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina BR112015010283A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723408P 2012-11-07 2012-11-07
PCT/EP2013/073266 WO2014072405A1 (en) 2012-11-07 2013-11-07 Production of recombinant vaccine in e. coli by enzymatic conjugation

Publications (2)

Publication Number Publication Date
BR112015010283A2 true BR112015010283A2 (pt) 2017-07-11
BR112015010283A8 BR112015010283A8 (pt) 2021-07-06

Family

ID=49552366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010283A BR112015010283A8 (pt) 2012-11-07 2013-11-07 bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina

Country Status (16)

Country Link
US (2) US20150273043A1 (pt)
EP (3) EP2917351B1 (pt)
JP (2) JP6412875B2 (pt)
KR (1) KR20150079964A (pt)
CN (1) CN105008539B (pt)
AU (2) AU2013343520B2 (pt)
BR (1) BR112015010283A8 (pt)
CA (2) CA3125293A1 (pt)
EA (1) EA201590705A1 (pt)
ES (3) ES2713166T3 (pt)
IL (1) IL238586A0 (pt)
MX (1) MX366912B (pt)
SG (1) SG11201503308XA (pt)
TR (1) TR201903066T4 (pt)
WO (1) WO2014072405A1 (pt)
ZA (1) ZA201503097B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038456T2 (hu) * 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
CN106794237B (zh) * 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 经修饰的宿主细胞及其用途
US10307474B2 (en) * 2014-08-08 2019-06-04 Glaxosmithkline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
AU2016224006B8 (en) * 2015-02-26 2020-03-19 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
CN105963691B (zh) * 2016-07-03 2020-05-01 查文娟 一种肺炎链球菌疫苗
CN106929573B (zh) * 2017-02-21 2020-06-09 南开大学 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用
GB201712678D0 (en) * 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
EP3703745B1 (en) * 2017-11-04 2024-04-10 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CA3103474A1 (en) * 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines
JP2022514704A (ja) * 2018-12-21 2022-02-14 ヴァックスニューモ エルエルシー Ｏ結合型グリコシル化認識モチーフ
AU2020240075A1 (en) * 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CN111518738B (zh) * 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031548A1 (en) * 1994-05-16 1995-11-23 The Uab Research Foundation Streptococcus pneumoniae capsular polysaccharide genes and flanking regions
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
SG10201400320TA (en) 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
CA2756170C (en) * 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
CA2768263C (en) 2009-07-17 2015-05-12 Ocean Harvest Technology (Canada) Inc. Natural and sustainable seaweed formula that replaces synthetic additives in fish feed
HUE037956T2 (hu) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák
ES2905107T3 (es) * 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras

Also Published As

Publication number Publication date
EP3508579B1 (en) 2021-06-30
AU2017279688B2 (en) 2019-11-14
CA3125293A1 (en) 2014-05-15
JP6412875B2 (ja) 2018-10-24
EP3508579A1 (en) 2019-07-10
KR20150079964A (ko) 2015-07-08
CN105008539B (zh) 2020-04-17
JP2019030309A (ja) 2019-02-28
MX2015005797A (es) 2016-03-09
BR112015010283A8 (pt) 2021-07-06
US10973901B2 (en) 2021-04-13
AU2013343520B2 (en) 2017-09-28
ES2713166T3 (es) 2019-05-20
CA2889767A1 (en) 2014-05-15
EP3444352A3 (en) 2019-03-27
JP2015533511A (ja) 2015-11-26
US20190076517A1 (en) 2019-03-14
TR201903066T4 (tr) 2019-03-21
EP2917351A1 (en) 2015-09-16
WO2014072405A1 (en) 2014-05-15
EP3444352A2 (en) 2019-02-20
EP3444352B1 (en) 2020-12-16
ES2848774T3 (es) 2021-08-11
ES2882282T3 (es) 2021-12-01
AU2013343520A1 (en) 2015-06-04
CN105008539A (zh) 2015-10-28
JP6833785B2 (ja) 2021-02-24
US20150273043A1 (en) 2015-10-01
ZA201503097B (en) 2018-11-28
EA201590705A1 (ru) 2016-05-31
EP2917351B1 (en) 2018-12-19
CA2889767C (en) 2021-09-21
MX366912B (es) 2019-07-30
SG11201503308XA (en) 2015-05-28
IL238586A0 (en) 2015-06-30
AU2017279688A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
BR112015010283A2 (pt) bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, método de produzir uma glicoproteína recombinante, e, célula de e. coli modificada
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
PH12016501671A1 (en) Novel polysaccharide and uses thereof
MY191370A (en) Production of odd chain fatty acid derivatives in recombinant microbial cells
BR112017025614A2 (pt) método para produzir glicosídeo de esteviol e composição
MX351565B (es) Colageno 7 y metodos relacionados.
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
PH12015500636A1 (en) Nutritional compositions including a calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
MY180625A (en) Algal lipid compositions and methods of preparing and utilizing the same
IN2012DN02210A (pt)
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112017001550A2 (pt) enxerto de tecido
MY182946A (en) Production of organic acids by fermentation at low ph
SG10201901713RA (en) Extracellular matrix compositions
MX2020001357A (es) Produccion microbiana de aminas grasas.
AU2018201444B2 (en) High fat human milk products
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EP4282972A3 (en) Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells
WO2011123811A3 (en) Production of post-translationally hydroxylated recombinant proteins in bacteria
BR112014004123A2 (pt) micro-organismos das espécies bacteroides xylanisolvens
BR112023017385A2 (pt) Cápsula bem como sua produção e uso
MX2014007760A (es) Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas.
MX2014010958A (es) Composicion de celulas inmunoestimuladora activada y sus usos.
BR112013001544A2 (pt) produção baseada em planta de proteínas heterólogas.
MX2014013843A (es) Produccion de hidrofobina a partir de trichoderma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA (BE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.